News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Graham Nicholls Joins Almac Clinical Technologies as Director of Biostatistics



4/21/2010 11:42:57 AM

YARDLEY, PA--(Marketwire - April 21, 2010) - Almac's Clinical Technologies business unit announced today that Graham Nicholls has joined the company as Director of Biostatistics. Mr. Nicholls possesses over fifteen years of experience in the biopharmaceutical industry, serving in a variety of capacities including biostatistics, product management, and client account management. He will head Almac's biostatistical department and will be responsible for consulting with clients on trial design, randomization and drug supply strategies, adaptive trial implementation, and the application of statistical methods to improve clinical trial management.

Mr. Nicholls joins Almac after spending several years at GlaxoSmithKline (GSK) as a Senior Statistician, HIV/Infectious Diseases and close to ten years at Clinphone and Perceptive Informatics. At Clinphone and later Perceptive Informatics, Mr. Nicholls served several roles including Senior Statistician, Product Manager of Randomization & Trial Supply Management, and Director of Client Account Management.

Jim Murphy, President of Almac Clinical Technologies, comments on Mr. Nicholls joining Almac: "We are very happy to have Graham at Almac. He is a highly experienced and reputable addition to our Biostatistical Department. Graham will serve a vital function by providing our clients with world-class knowledge and credible consulting on a range of biostatistical and clinical trial management issues. By joining Almac, Graham takes our IXRS offering to a new level."

Almac welcomes Mr. Nicholls during a period of rapid growth for both the Clinical Technologies business unit and the larger Almac Group. Graham brings considerable experience in adaptive trial designs, covariate adaptive (dynamic) randomization techniques, and other complex trial designs, an enduring strength of Almac. He also will contribute to Almac's integrated drug supplies and technology offering, which helps clients optimize their clinical supply chains and reduce costs.

Alan Armstrong, CEO of Almac, speaks of Mr. Nicholls responsibilities: "Graham will play a key role in our integrated services strategy by providing highly advanced biostatistical and trial design consulting to clients wishing to optimize their clinical trial supply chain. His expertise will also be applied to our integrated biomarkers, adaptive trial design and clinical technologies offerings. I warmly welcome Mr. Nicholls to the Almac family and anticipate he will make a huge impact here."

Graham Nicholls' professional experience includes authoring several articles on adaptive trials, drug supply management, and utilizing simulation techniques to optimize the supply chain. He has spoken at over 20 professional conferences in the past few years, and has participated in a variety of industry webinars on Interactive Voice Response and Web Response (IVR/IWR) technologies, adaptive trial designs, drug supply forecasting and management, and other topics.

About Almac Clinical Technologies
Almac Clinical Technologies is a division of the Almac Group that specializes in interactive technology and service solutions to increase the quality and efficiency of the clinical trial process. Our solutions include Interactive Voice and Web Response Systems (IXRS™) for patient randomization, tracking and clinical supply management; electronic patient reported outcomes data collection; and Web drug reconciliation. Almac's technologies have been deployed in over 1450 clinical trials, incorporating over 1.5 million patients in over 80 countries and more than 60 languages.

About Almac Group:
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS & Web), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 2,600 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company's new $120m North American Headquarters started in July 08 and is expected to be completed 2010. Almac was awarded Northern Ireland's "Business of the Year" award in 2009.

For more information about the Almac Group, please visit www.almacgroup.com or e-mail info@almacgroup.com.


Contact:
Meghan Adams
T: (001) 267-685-4284
E: Email Contact
W: www.almacgroup.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES